Is PLX (PLX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 16.5% / 30% | 1.4% / 30% | 2.43% / 5% | ✓ HALAL |
| DJIM | 2.6% / 33% | 16.5% / 33% | 1.4% / 33% | 2.43% / 5% | ✓ HALAL |
| MSCI | 7.5% / 33% | 47.4% / 33% | 4.0% / 33% | 2.43% / 5% | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 16.5% / 33% | 1.4% / 33% | 2.43% / 5% | ✓ HALAL |
| FTSE | 7.5% / 33% | 47.4% / 33% | 4.0% / 50% | 2.43% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 13.0% | |
| Operating Margin | -51.1% | |
| Net Margin | -12.5% | |
| Return on Equity (ROE) | -14.4% | |
| Return on Assets (ROA) | -4.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $9M |
| Free Cash Flow | $7M |
| Total Debt | $6M |
| Debt-to-Equity | 17.3 |
| Current Ratio | 2.5 |
| Total Assets | $73M |
Price & Trading
| Last Close | $2.11 |
| 50-Day MA | $2.60 |
| 200-Day MA | $2.01 |
| Avg Volume | 1.3M |
| Beta | -0.2 |
|
52-Week Range
$1.32
| |
About PLX (PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Purification Calculator
As a halal stock with 2.43% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is PLX (PLX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), PLX is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is PLX's debt ratio?
PLX's debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 7.5%.
Does PLX require dividend purification?
Yes, PLX has an impermissible income ratio of 2.43%, which means 2.43% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are PLX's key financial metrics?
PLX has a market capitalization of $172M, and revenue of $53M. The company maintains a gross margin of 13.0% and a net margin of -12.5%. Return on equity stands at -14.4%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.